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A B S T R A C T 
 
Osteoporosis is an important health problem, and the number of patients who 
suffered from it is increasing. Breast cancer is a condition that has a  high risk of 
osteoporosis. Cancer induced bone disease results from the primary disease, 
metastatic process, or from therapies against the prime condition, causing bone 
fragility. Therefore, there are still different opinions regarding the therapeutic 
effect of breast cancer on bone mineral density. Aim: to determine the effect of 
chemotherapy and hormonal therapy on bone mineral density in patients with 
breast cancer in Saiful Anwar Hospital Malang. Method: this is a case-control study 
conducted in 30 patients with breast cancer who had undergone chemotherapy and 
hormonal therapy are compared to 30 patients without breast cancer as controls.  
Bone Mineral Density (BMD) was measured by DEXA. Result: there are 53% of 
breast carcinoma patients having osteopenia and 13% having osteoporosis, with 
one patient has osteoporosis located in the femoral neck and three patients in 
lumbar (L1-L4). We obtain a significant T-score (p=0.02) in the great trochanter. 
Odds Ratio (OR) 0.233 with p = 0.008 showed a protective effect of chemotherapy 
and hormonal therapy for breast cancer to the bone density. Conclusion: the 
incidence of osteoporosis in the study was 13%, with the most location in the 
lumbar spine. Chemotherapy and hormonal therapy had a protective effect on BMD 
in patients with breast cancer in Saiful Anwar Hospital Malang. 
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I N T R O D U C T I O N 
 Osteoporosis or porous bone is a disorder 
characterized by increased skeletal fragility as a 
result of decreased bone quantity and quality. 
World Health Organization (WHO) defines 
osteoporosis as a bone metabolic disease that often 
occurs, characterized by decreased bone mass and 
changes in bone tissue microarchitecture due to 
increased bone fragility and tendency to experience 
fractures.[1,2] 
 
The increasing incidence of osteoporosis 
makes osteoporosis as a global health issue.[3.4] 
Based on an analysis of risk data for Osteoporosis in 
the Indonesian Ministry of Health's Nutrition 
Research and Development Center, the prevalence of 
osteoporosis in Indonesia reaches 41.75%It shows 
that 2 out of 5 Indonesians are at risk for 
osteoporosis, and this figure is higher than the global 
prevalence of which only 1 in 3 is at risk of 
osteoporosis.[5,6,7] WHO defines osteoporosis based 
on bone mineral density (BMD).  
There are 4 categories of bone density 
diagnosis based on T-scores[6,8,9,10] : 
1. Normal: T-score is greater than or equal to -1 SD. 
2. Osteopenia (low bone mass): T-score between -1 
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SD to -2.5 SD. 
3. Osteoporosis: T-score below -2.5 SD. 
4. Advanced osteoporosis: T-score below -2.5 SD in 
the presence of one or more osteoporotic 
fractures. 
Cancer patients are one part of the increase 
in patients newly diagnosed with osteoporosis. 
Postmenopausal breast carcinoma patients have a 
high risk of osteoporosis. It was caused by breast 
carcinoma, side effects of anti-cancer therapy, and 
post menopause.[11] 
A bone microenvironment is a good place 
for the growth of malignant cells originating from 
distant tumors (metastases). In 1879, Stephan 
Paget mentioned that carcinoma cells had an 
increased migration and spread to the bone. Bone 
metastases are usually classified into osteolytic, 
osteoblastic/osteosclerotic, or mixed types. In 
breast carcinoma, the type of metastasis is a mixed-
type. 
The effects of chemotherapy cause 60-65% 
of women who get the CMF (Cyclophosphamide-
methotrexate-5 fluorouracil) regimen and 50% 
with the FAC (5-Fluorouracil-doxorubicin 
Cyclophosphamide) regimen to ovarian damage. 
Permanent ovarian damage is obtained by 
chemotherapy using cyclophosphamide, 
chlorambucil, and mitomycin C. [12,13,14] 
Hormonal therapy using tamoxifen is 
associated with bone loss through its anti-selective 
estrogen receptor modulator (SERM) effects that 
are agonist and antagonistic to estrogen receptors. 
Besides Tamoxifen, aromatase inhibitors (AI) are 
also used in breast carcinoma. Aromatase inhibitors 
(AI) are responsible for the aromatization of 
androgens into estrogens in peripheral tissues. AI 
causes bone loss faster and heavier than normal 
processes in postmenopausal women. [15] 
The other causes of osteoporosis are the use 
of glucocorticoids. It was often used as analgesics, 
palliative agents, antiemetics, or as part of therapy. 
Glucocorticoids initially increase bone resorption, 
then suppress osteoblast activity and eventually 
suppress bone formation. 
M E T H O D S 
Patient and Method 
Thirty female breast carcinoma patients 
with positive ER and HER2 negative who have 
undergone outpatient chemotherapy and hormonal 
therapy in the haematology department of Internal 
Medicine, Saiful Anwar Hospital Malang, and 30 
women without breast carcinoma as controls were 
included in this study. 
The research design used was case-control study. All 
participants conducted BMD examination with a 
DEXA device, then measured the bone mineral 
density values. 
Statistical analysis 
Data is presented in mean and standard 
deviation. Unpaired categorical comparative data 
were analyzed by a Chi-square test (normal data 
distribution) and Mann Whitney (abnormal data 
distribution), the p-value was considered significant 
if p <0.05. Bivariate analysis with Chi-square test 
that produces OR is used to determined effects of 
chemotherapy and hormonal therapy on BMD 
changes. All technical data processing results were 
analyzed by computerization using Statistical 
Product and Service Solution software, IBM SPSS 
Statistics 20 with a significance level of 0.05 (p = 
0.05) and a confidence level of 95% (α = 0.05). 
R E S U L T S  
In this study there were 30 female patients 
with breast carcinoma who had undergone 
chemotherapy and hormonal therapy with 
tamoxifen, and 30 women without breast carcinoma 
as controls. 







Age  49.33 ± 3.76 49.87 ± 4.59 0.625 
Height 156.77 ± 4.04 153.97 ± 3.78 0.009 
Weight  59.37 ± 9.36 59.90 ± 12.49 0.852 
BMI 24.14 ± 3.64 25.19 ± 4.94 0.352 
BMI (n %)    
- Under  2 (3.3%) 2 (3.3%) 0.312 
- Normal 17 (28.3%) 10 (16.7%)  
- Over 9 (15%) 14 (23.3%)  
- Obesity 2 (3.3%) 4 (6.7%)  
Menopause   
- no 18 (36%) 0 (0%) 
< 
0.001 
- yes 12 (14%) 32 (50%)  
Calcium intake   
- no  15 (25%) 17 (28.3%) 0.605 
- yes 15 (25%) 13 (21.7%)  
Data presented as mean ± SD, or number (%) 
The age range of the control group and the 
sample that participated in this study were 30 to 60 
years with an average of 49.87 ± 4.59 years 
(patients) and 49.33 ± 3.76 years (controls). The 
mean BMI values were 24.14 ± 3.64 kg/m2 
(patients) and 25.19 ± 4.94 kg/m2. Overall, breast 
carcinoma patients included in the sample 
experienced menopause, and from the control 
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group, there were 12 people (14%) who had 
menopause (Table 1). 
The chemotherapy used was FAC 
(fluorouracil-doxorubicin-cyclophosphamide) of 
18 patients and 12 patients with paxus-








Figure 1. BMD results of breast carcinoma patients 
 
(Figure 1) shows breast carcinoma patients 
who have a normal BMD value of 34%, 53% 
included in the osteopenia category, and 13% 
included osteoporosis. Osteoporosis examination 
sites were found in the femoral neck of 1 patient and 
3 patients in the lumbar (L1-L4). 
Table 2. Comparison of BMD values of breast carcinoma 
patients who have undergone chemotherapy and hormonal 
treatment compared with controls 
 
Variable  




Femoral neck 0.72 ± 0.11 0.69 ± 
0.09 
0.727 





0.62 ± 0.11 0.57 ± 
0.88 
0.540 
L1 0.76 ± 0.16 0.67 ± 
0.13 
0.158 
L2 0.82 ± 0.16 0.81 ± 
0.12 
0.684 
L3 0.87 ± 0.16 0.87 ± 
0.15 
0.529 
L4 0.80 ± 0.15 0.85 ± 
0.12 
0.228 
L1-L4 0.81 ± 0.14 0.82 ± 
0.12 
0.888 
Data presented as mean ± SD. Independent t-test. 
Based on (Table 2), BMD values of the 
femoral neck, ward, great trochanter, L1, L2, L3, L4, 
and total L1-L4 in the examination of bone mineral 
density obtained p-value> 0.05. It shows no 
significant difference between bone mineral density 
values in the femoral neck, ward, great trochanter, 
L1, L2, L3, L4, and L1-L4 of breast carcinoma 
patients who had undergone chemotherapy and 
hormonal treatment compared with controls. 
Table 3. Comparison of T-score of breast carcinoma patients 
who have undergone chemotherapy and hormonal treatment 
compared with controls 
 
Variable  
T score  
p-Breast Control 
cancer value 










































Data presented as mean ± SD. Independent t-test. 
Based on (Table 3), the value of T-score great 
trochanter, obtained p-value 0.02 (<0.05). It 
indicates that there is a significant difference in bone 
mineral density values in the great trochanter of 
breast carcinoma patients who had undergone 
chemotherapy and hormonal treatment compared 
with controls, but not obtained Significant 
differences in other locations. 
























7 (11.7)   
Total  36 
(60) 
24 (40)   
Chi-square test 
 (Table 4) shows the results of the Odds Ratio 
(OR) of 0.233 with a p-value of 0.008 which shows 
that in breast carcinoma patients who have 
undergone chemotherapy and hormonal therapy the 
incidence rate is significantly lower by 0.233 times 
compared to normal controls. 
 
 
D I S C U S S I O N 
 This study aims to determine the effect of 
chemotherapy and hormonal therapy on breast 
carcinoma on bone mineral density in evaluating the 
possibility of decreasing bone mineral density (in 
this case osteoporosis) in breast carcinoma patients 
with ER + and HER2-. The number of samples 
collected from the August-September 2015 period 
were 30 female patients with breast carcinoma in 
poly haematology oncology of dr. Saiful Anwar, 
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chemotherapy and hormonal therapy and 30 people 
without breast carcinoma as controls. All included 
in this study were those that met the study inclusion 
criteria, and those who were not included in the 
inclusion criteria were immediately excluded as the 
study sample. 
The age range of the control group and the 
sample that participated in this study were 30 to 60 
years with an average of 49.87 ± 4.59 years 
(patients) and 49.33 ± 3.76 years (controls). The 
mean BMI values were 24.14 ± 3.64 kg / m2 
(patient) and 25.19 ± 4.94 kg / m2 (Table 1). 
Description of bone mineral density in 
breast carcinoma samples with hormonal therapy is 
34% with normal BMD values, 53% osteopenia and 
13% including osteoporosis, with osteoporosis 
locations found in the femoral neck of 1 patient and 
3 patients in lumbar (L1-L4). The Spanik and 
Spanikova studies (with 8 times the number of 
study samples) have the same percentage of BMD 
osteopenia and osteoporosis, which is 43.35% with 
the most osteoporosis locations in the lumbar. 
Therapy of breast carcinoma causes bone loss as 
much as 2-20% annually. Loss of BMD during 
carcinoma therapy generally occurs more rapidly in 
the trabecular bone in the lumbar vertebra than in 
the cortical bone in the thigh (femur).[11,16,17] 
In this study, breast carcinoma patients who 
received FAC chemotherapy were 18 patients and 
12 patients with Paxus-doxorubicin, and all breast 
carcinoma patients received tamoxifen hormone 
therapy. Different types of breast carcinoma require 
different therapies and management. In breast 
carcinomas with oestrogen receptor positive, one 
part of the treatment includes ways to reduce 
oestrogen levels temporarily or permanently to 
prevent further carcinoma stimulation. 
Management of breast carcinoma (surgery, 
chemotherapy and hormonal therapy) is known to 
cause amenorrhea or early menopause.16,18 Drugs 
used in chemotherapy can cause permanent or 
temporary ovarian dysfunction. Chemotherapy 
related amenorrhea (CRA) based on the American 
College of Obstetricians and Gynaecologists is 
defined as the cessation of menstruation for 6 
months. Other literature defines cessation of 
menstruation for at least 3 months during or 
immediately after administration of adjuvant 
chemotherapy, cessation of menstruation 6, 8, or 12 
months, or cessation of menstruation during 
chemotherapy and no further menstruation. 
[13,17,19,20,21] 
Chemotherapy can cause ovarian atrophy 
and loss of primordial follicles, and damage to 
ovarian pregranulosa cells due to injury to blood 
vessels and focal fibrosis of the ovarian cortex 
caused by exposure to chemotherapy. Follicular 
damage due to chemotherapy may cause permanent 
menstruation, temporary amenorrhea, irregular 
menstruation (perimenopause), or complete 
ovarian failure (menopause). Although the 
mechanism is not fully understood, in vitro studies 
show that changes in apoptosis in pregranulosa cells 
result in direct destruction of the follicle. In short 
chemotherapy causes destruction of primordial 
follicles and decreased follicular maturation. [19,20,22] 
(Table 3) shows no effect of hormone 
therapy given on bone mineral density in the 
femoral neck, ward, L1, L2, L3, L4, and L1-L4, this is 
seen with the presence of p-value> 0.05 in the 
comparison of control and patient groups. However, 
in the great trochanter, a p-value of 0.02 (<0.05) 
was obtained which showed that there was an effect 
of chemotherapy and hormonal therapy on bone 
mineral density. Odds Ratio (OR) 0.233 with p-value 
0.008 in shows the protective effect of 
chemotherapy and hormonal therapy on breast 
carcinoma on decreasing bone mineral density. This 
is indeed contrary to previous studies. In a study 
conducted by Hadji (2009) and Giuse (2006) states 
that the provision of hormonal therapy as a therapy 
for women with breast carcinoma showed a 
decrease in bone mineral density and increased risk 
of fractures. However, in a study conducted by 
Chandra (2012) regarding the singh index accuracy 
compared to DEXA in the examination of 
osteoporosis in patients with breast carcinoma, it 
was stated that there was no relationship between 
hormonal therapy and decreased bone mineral 
density. [20,23,24] 
The study of Spanik and Spanikova (2010), 
Body (2010), Hadji et al. (2012), and Inoue et al. 
(2015) showed a rapid decrease in bone mineral 
density in the first 1-3 years of hormonal therapy. 
BMD decreases in the range of 0.5 - 4% per year. And 
after that the decrease in BMD will run more slowly. 
The rapid decline at the start of hormonal therapy is 
thought to be due to a rapid decrease in oestrogen 
levels in the premenopausal stage to the menopause 
stage. After the initiation of hormonal therapy in 
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breast carcinoma, a rapid decline in oestrogen 
occurs within 3 weeks and causes a rapid and 
significant loss of bone mass. This happens because 
oestrogen indirectly regulates bone resorption 
activity by osteoclasts, where a decrease in 
oestrogen levels will increase the amount of bone 
resorption. After menopause, low residual 
oestrogen levels are known to be important for 
maintaining bone density, and carcinoma therapy 
that decreases oestrogen can have a negative effect 
on bone.[11,16,17,25,26] 
The protective effect of hormonal therapy 
seen in table 14 can be caused by the use of 
tamoxifen as a hormonal therapy. Tamoxifen is said 
to be more a Selective Oestrogen Receptor 
Modulator (SERM) than an antioestrogen. SERMs 
are structurally divided into groups that bind both 
ERα and ERβ and produce oestrogen agonist effects 
in some tissues, but have oestrogen antagonistic 
activity in other tissues. ERα is expressed in 
osteoblasts and osteoclasts, and ERβ is expressed in 
osteoblasts, showing a direct effect of oestrogen on 
bone metabolism. Tamoxifen as a SERM in breast 
carcinoma has anti-tumor effects including its 
ability as an antagonist to oestrogen proliferation 
through competitive binding to oestrogen 
receptors. In contrast tamoxifen has agonist activity 
in the spine, uterus and some cardiovascular risk 
markers. The pharmacology of SERM can be 
explained through interactive mechanisms: 
differences in ER expression in target tissues, 
differences in ER conformation in ligand bonds, and 
differences in expression and bonds in oestrogen 
coregulator proteins.[27,28] In breast carcinoma, 
tamoxifen competitively binds to oestrogen 
receptors and works as an anti-proliferative in 
breast epithelium. Tamoxifen also has estrogen-like 
effects on bones and maintains bone mineral 
density.[29] In the COBRA (Consortium on Breast 
Cancer Pharmacogenomics) study, tamoxifen 
caused a greater increase in BMD of breast 
carcinoma patients undergoing chemotherapy than 
those without. This increase in BMD may be due to 
chemotherapy affecting changes in bone 
metabolism and ovarian function that cause 
additional effects of oestrogen on the bones. 
Tamoxifen increases BMD in Lumbar in 
postmenopausal women as in women with breast 
carcinoma by decreasing bone turnover. A 
significant increase in BMD is found in the lumbar 
which is a trabecular bone and not at the tip of the 
femur which is predominantly cortical bone.[30] 
This study has various limitations. Some 
things that need attention are the limitations in this 
study, among others: more number of research 
samples needed to better be able to see the 
relationship of the effects of hormonal therapy on 
bone mineral density, duration of hormonal therapy 
administration, nutrition (actual calcium intake) 
and physical activity were not evaluated thus 
affecting the bone mass density of the sample, and 
the need for a density examination before the 
treatment of breast carcinoma (baseline BMD) and 
during therapy to evaluate the bone mineral density. 
In conclusion, that chemotherapy and 
hormonal therapy have a protective effect on the 
bone mineral density of breast carcinoma patients in 
Saiful Anwar Hospital, Malang. 
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